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condensationAbstract A novel series of 1-{[3-(furan-2-yl)-5-substituted phenyl-4,5-dihydro-1,2-oxazol-4-
yl]methyl}-4-methyl piperazine, compounds 3a–l have been synthesized. The synthetic work was car-
ried out beginning from 2-acetylfuran through Claisen Schmidt condensation with different types of
aromatic aldehyde, affording 1-(furan-2-yl)-3-substitutedphenylprop-2-en-1-ones which on cyclization
with hydroxylamine hydrochloride resulted in 3-(furan-2-yl)-5-substitutedphenyl-4,5-dihydro-1,2-oxa-
zole formation. The isoxazolines were subjected to Mannich’s reaction in the presence of N-methyl
piperazine to produce the desired product. The chemical structures of the compounds were proved
by IR, 1H NMR, 13C-NMR and Mass spectrometric data. The antidepressant activities of the com-
poundswere investigated byPorsolt’s behavioral despair (forced swimming) test on albinomice.More-
over, the antianxiety activity of the newly synthesized compounds was investigated by the plus maze
method. Compounds 3a and 3k reduced the duration of immobility times of 152.00–152.33% at
10 mg/kg dose level and compounds 3a and 3k have also shown signiﬁcant antianxiety activity.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Considerable approaches have passed during the past two dec-
ades in the pharmacological treatment of anxiety and depres-
sion. Depression is a state of low mood and aversion to
activity that can have a negative effect on a person’s thoughts,
behavior, feelings, world view and physical well-being. World
Health Organization calculates that by 2020 depression will
be the second most disabling condition in the world (Rozas,
142 J. Kumar et al.2009). Based on these statistics, it is clear that there is a de-
mand for new drug candidates in the treatment of depression
(Kennedy and Rizvi, 2009). Contempt these advances, unmet
medical needs still survive for the treatment of anxiety and
depression. Among the deﬁciencies of modern drugs are slow
onset of action, lack of success in refractory patients, and pres-
ence of unwanted gastrointestinal and sexual side effects. In
addition, anxiety and depression are conceived to be different
neuropsychiatric diseases, there is considerable overlap among
the clinical symptoms of these disorders and differential diag-
nosis is often difﬁcult (Tyrer, 1992). Anxiety often coexists
with depression or may precede the development of depressive
symptoms (Nutt and Glue, 1989) and anxiety and depression
may be biochemically colligated since there are many similar-
ities in the neurological substrates thought to play a role in
these diseases, (Glennon and Dukat, 1995; Heninger, 1995;
Sleight et al., 1991; Siever et al., 1991; Perregaard et al.,
1993; Glennon, 1990; Zifa and Fillion, 1992) including a recent
report describing a polymorphism in the serotonin transporter
gene associated with both anxiety and depression-related per-
sonality traits (Lesch, 1998). In accession, anxiolytic agents
may have utility in treating depression, (Charney et al., 1990)
and there is developing clinical evidence that antidepressants
may be effective in treating generalized anxiety disorder (Ric-
kels et al., 1993). Monoamine oxidase inhibitors (MAOIs) ini-
tially were the ﬁrst line medications in the treatment of
depressive illness, however, due to serious side effects, the
interest in these drugs lessened (Coutts et al., 1986). Because
of potentially lethal dietary and drug interactions, monoamine
oxidase inhibitors have historically been reserved as a last line
of treatment, used only when other classes of antidepressant
drugs (for example selective serotonin reuptake inhibitors
and tricyclic antidepressants) have failed. When the two iso-
forms, MAO-A and MAO-B, were discovered, interest was re-
newed in their potential therapeutic employment, and several
new generations of selective MAO inhibitors have evolved
(Youdim et al., 2006). There is growing evidence for a beneﬁ-
cial therapeutic effect of MAO-B speciﬁc inhibitors in the
treatment of patients suffering with early stages of Parkinson’s
disease (Youdim et al., 2006). There is an increased interest in
the development of potent and selective MAOIs, due to this in-
creased consciousness of neurological disease states. Reversible
selective MAO-A inhibitions are employed as antidepressant
and antianxiety drugs (Rudorfer and Potter, 1989), and selec-
tive MAO-B inhibitors are coadjuvant in the treatment of Par-
kinson’s disease and perhaps also in Alzheimer’s disease
(Wouters, 1998; Tetrud and Langston, 1989). Isocarboxazide
is an irreversible and nonselective monoamine oxidase inhibi-
tor (MAOI) of the hydrazine chemical class employed as an
antidepressant and anxiolytic (Fagervall and Ross, 1986). A
number of isoxazole derivatives are experienced to have anti-
depressant, antianxiety (Garvey et al., 1994; Wagner et al.,
2004; Andres et al., 2007; Ignacio and Gil, 2004, 2007, 2008;
Sheeja Mary et al., 2011) anti-stress (Maurya et al., 2011), anti-
convulsant (Balalaie et al., 2000), antiviral (Lee et al., 2009),
anti-inﬂammatory (Dannahardt et al., 2000), anti-inﬂamma-
tory and analgesic activities (Jayashankar et al., 2009).
The target compounds were designed based on the fact that
isocarboxazide develops an inhibition of monoamine oxidase
in in-vitro and in-vivo studies, and isocarboxazide is an isoxazole
derivative. Additionally, docking analysis facilitates under-
standing the nature of interactions governing the binding ofthe designed molecule with the MAO-A enzyme. On the basis
of this context, the present work has been aimed to synthesize
some novel 1-{[3-(furan-2-yl)-5-substituted phenyl-4,5-dihy-
dro-1,2-oxazol-4-yl]methyl}-4 methyl piperazine derivatives.
The synthesized compounds were characterized by IR, 1H
NMR, 13CNMR,MS and elemental analysis. Their antidepres-
sant and anxiolytic activities were evaluated by the FST and the
plusmazemethods respectively. To evaluate their receptor bind-
ing study, compounds with a diversiﬁedMAO functional proﬁle
were chosen and examined using common behavioral tests for
predicting antidepressant and/or anxiolytic like activities in
mice. Furthermore, molecular modeling studies using synthe-
sized isoxazole derivatives were performed to predict the pre-
ferred binding modes of compounds with MAO-A.
2. Experimental
2.1. Chemistry
All the chemicals used were of laboratory grade and procured
from E. Merck (Germany) and S.D. Fine Chemicals (India).
Melting points were determined by the open tube capillary
method and are uncorrected. The thin layer chromatography
(TLC) plates (silica gel G) were used to justify the purity of
commercial reagents used, compounds synthesized and to
monitor the reaction progress. Two different solvent systems:
toluene:ethyl acetate:formic acid (5:4:1) and benzene:acetone
(9:1) were used to run the TLC and spots were located under
iodine vapors/UV light. An IR spectrum was obtained on a
Perkin–Elmer 1720 FT-IR spectrometer (KBr Pellets). Ele-
mental analyses were carried out on a Perkin–Elmer 2400 ana-
lyzer (USA) and were found within ±0.5% of the theoretical
values. 1H NMR and 13C NMR spectra were recorded in
DMSO-d6 on a Bruker 400 and 75 MHz spectrometer, respec-
tively, using tetramethylsilane (TMS) as the internal reference
(chemical shift was measured in d ppm). Mass spectra (ESI-Q-
TOF) were measured on a Waters mass spectrometer with an
ESI (Electron spray ionization) source.
2.2. General procedure for the preparation of 1-(furan-2-yl)-3-
substituted phenylprop-2-en-1-ones (1a–l)
2.2.1. Step I. Preparation of chalcones facilitates Claisen
Schmidt condensation
A mixture of 2-acetylfuran (0.01 mol) and appropriate alde-
hydes (0.01 mol) in oxygen-free methanol (30 mL) was stirred
at room temperature in the presence of base (aqueous solution
of potassium hydroxide 40%; 15 mL) till completion of the
reaction. The reaction mixture was kept overnight at room
temperature and then poured into crushed ice followed by neu-
tralization with HCl. The solid separated was ﬁltered, dried
and crystallized from ethanol. The purity of the chalcones
was checked by TLC.
2.2.2. Step II. Cyclization with hydroxylamine hydrochloride
To a solution of compounds 1a–l (0.01 mol) in absolute etha-
nol (50 ml), dry pyridine (1 ml) and hydroxylamine hydrochlo-
ride (0.01 mol) were added. The reaction mixtures were
reﬂuxed for 8–10 h at 80 C and cooled in a refrigerator over-
night. The solvent was evaporated, and reaction mixture was
then poured into ice-cold water. The obtained precipitate
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was recrystallized from methanol.
The IR spectrum of compound (2a) showed an absorption
peak at 1352 cm1 due to C–O–N, 1656 cm1 for C‚N and
1052 cm1 for C–O–C stretching vibration. The structure
was further conformed by its 1H NMR spectrum, which
showed two double doublets at d 3.56 and d 3.71 for CH2 pro-
tons of isoxazoline ring. The CH proton at C-5 of isoxazoline
was obtained as a triplet at d 6.04. Thus, disappearance of sig-
nals of the oleﬁnic protons and appearance of CH2 and CH
proton signals in the spectrum conﬁrmed the formation of
isoxazoline ring. The mass spectrum of the compound 2a
showed a molecular ion peak M+ at m/z 213 corresponding
to molecular formula C13H11NO2.
2.2.3. Step III. Mannich’s reaction involved for the preparation
of ﬁnal derivative (3a–l)
To a solution of compounds 2a–l (0.01 mol) in methanol
(50 ml), formaldehyde (0.02 mol) and 1-methyl piperazine
(0.01 mol) were added. The reaction mixture was reﬂuxed for
6 h. the solvent was distilled off, and the residue was poured
into ice water. The precipitated solid was ﬁltered off, dried
and recrystallized from appropriate solvents. All the synthe-
sized compounds were puriﬁed by suitable solvents. Purity of
compounds was checked by TLC. The physico-chemical data
were presented in Table 1.
2.3. Characterization of synthesized derivatives
2.3.1. 1-{[3-(furan-2-yl)-5-phenyl-4,5-dihydro-1,2-oxazol-4-
yl]methyl}-4 methyl piperazine (3a)
FT-IR (KBr pellet) cm1: 3126 (aromatic C–H stretch), 1686
(C‚N stretch), 1362 (C–O–N stretch), 1048 (furan C–O–CTable 1 Physicochemical parameters of the synthesized compounds
N
N
N
O
H3C
Compd. No. R Yielda (%) m.p. (C)
3a H 68 122–123
3b 4-CH3 60 134
3c 2-Cl 58 142
3d 4-Cl 54 138–140
3e 4-Br 68 108
3f 4-F 65 94–95
3g 4-OH 50 70–72
3h 4-OCH3 64 102
3i 4-NH2 66 128–129
3j 4-NO2 72 138
3k 4-N(CH3)2 69 142–144
3l 3,4-(OCH3)2 56 116
a After recrystallization from ethanol.
b ACD/CLogP 12.0 software.
c Toluene:ethyl acetate:formic acid (5:4:1).stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.89–7.72 (t, 3H, furan), 7.61–7.03 (m, 5H, Ar–H),
5.34 (d, 1H, isoxazoline, J= 6.7 Hz), 4.29 (m, 1H, isoxazo-
line), 3.41 (d, 2H, J= 6.2 Hz (CH2–N), 3.27–2.54 (t, 8H,
J= 4.6 Hz CH2–N–CH2 piperazine), 2.51 (s, 3H, N–CH3
piperazine); 13C NMR (75 MHz, DMSO-d6): d (ppm) 149.92
(C), 145.40 (C), 142.46 (C), 139.57 (C), 129.74 (2C), 129.24
(C), 128.99 (2C), 119.43 (C), 104.14 (C), 84.53 (C), 53.76
(2C), 51.93 (2C), 51.82 (C), 46.76 (C); ESI-MS: m/z 325
(M+); Anal. Calcd. for C19H23N3O2: C, 70.13, H, 7.12, N,
12.91, Found C, 70.12, H, 7.11, N, 12.93%.
2.3.2. 1-{[3-(furan-2-yl)-5-(4-methylphenyl)-4,5-dihydro-1,2-
oxazol-4-yl]methyl}-4 methyl piperazine (3b):
FT-IR (KBr pellet) cm1: 3116 (aromatic C–H stretch), 1680
(C‚N stretch), 1359 (C–O–N stretch), 1052 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.80–7.62 (t, 3H, furan), 7.41–7.12 (m, 4H, Ar–H),
5.38 (d, 1H, isoxazoline J= 6.9 Hz), 4.20 (m, 1H, isoxazoline),
3.47 (d, 2H, J= 6.0 Hz (CH2–N), 3.37–2.48 (t, 8H,
J= 4.3 Hz CH2–N–CH2 piperazine), 2.86 (s, 3H, Ar–CH3),
2.48 (s, 3H, N–CH3 piperazine);
13C NMR (75 MHz,
DMSO-d6): d (ppm) 150.02 (C), 146.34 (C), 142.36 (C),
139.51 (C), 130.14 (2C), 129.20 (C), 129.09 (2C), 119.40 (C),
104.24 (C), 84.13 (C), 53.70 (2C), 52.13 (2C), 52.42 (C),
46.16 (C); ESI-MS: m/z 339 (M+); Anal. Calcd. for
C20H25N3O2: C, 70.77, H, 7.42, N, 12.38, Found C, 70.74,
H, 7.38, N, 12.35%.
2.3.3. 1-{[3-(furan-2-yl)-5-(2-chlorophenyl)-4,5-dihydro-1,2-
oxazol-4-yl]methyl}-4 methyl piperazine (3c):
FT-IR (KBr pellet) cm1: 3096 (aromatic C–H stretch), 1678
(C‚N stretch), 1342 (C–O–N stretch), 1068 (furan C–O–C(3a–l).
O
R
Mol. formula Mol. wt log Pb Rf
c
C19H23N3O2 325.40 0.87 ± 0.64 0.39
C20H25N3O2 339.43 1.33 ± 0.64 0.43
C19H22ClN3O2 359.84 1.46 ± 0.64 0.36
C19H22ClN3O2 359.84 1.46 ± 0.64 0.42
C19H22BrN3O2 404.30 1.64 ± 0.66 0.37
C19H22FN3O2 343.39 0.92 ± 0.66 0.41
C19H23N3O3 341.40 0.13 ± 0.64 0.38
C20H25N3O3 355.43 0.78 ± 0.64 0.39
C19H24N4O2 340.41 0.41 ± 0.64 0.41
C19H22N4O4 370.40 0.60 ± 0.64 0.37
C21H28N4O2 368.47 0.98 ± 0.65 0.38
C21H27N3O4 385.45 0.61 ± 0.65 0.39
144 J. Kumar et al.stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.69–7.52 (t, 3H, furan), 7.36–7.13 (m, 4H, Ar–H),
5.64 (d, 1H, J= 7.0 Hz isoxazoline), 4.16 (m, 1H, isoxazo-
line), 3.48 (d, 2H, J= 6.2 Hz (CH2–N), 3.22–2.34 (t, 8H,
J= 4.7 Hz CH2–N–CH2 piperazine), 2.58 (s, 3H, N–CH3
piperazine); 13C NMR (75 MHz, DMSO-d6): d (ppm)
150.02 (C), 141.48 (C), 141.36 (C), 136.87 (C), 129.84 (2C),
129.44 (C), 128.69 (2C), 119.39 (C), 103.94 (C), 83.98 (C),
54.06 (2C), 51.63 (2C), 51.64 (C), 47.06 (C); ESI-MS: m/z
359 (M+) and 361 (M + 2); Anal. Calcd. for C19H22ClN3O2:
C, 63.42, H, 6.16, N, 11.68, Found C, 63.39, H, 6.18, N,
11.65%.
2.3.4. 1-{[3-(furan-2-yl)-5-(4-chlorophenyl)-4,5-dihydro-1,2-
oxazol-4-yl]methyl}-4 methyl piperazine (3d)
FT-IR (KBr pellet) cm1: 3122 (aromatic C–H stretch), 1666
(C‚N stretch), 1336 (C–O–N stretch), 1064 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.68–7.32 (t, 3H, furan), 7.46–6.93 (m, 4H, Ar–H),
5.53 (d, 1H, J= 6.2 Hz isoxazoline), 4.32 (m, 1H, isoxazo-
line), 3.51 (d, 2H, J= 6.7 Hz (CH2–N), 3.43–2.64 (t, 8H,
J= 5.0 Hz CH2–N–CH2 piperazine), 2.56 (s, 3H, N–CH3
piperazine); 13C NMR (75 MHz, DMSO-d6): d (ppm)
150.02 (C), 142.64 (C), 142.24 (C), 140.05 (C), 130.14 (2C),
128.34 (C), 128.29 (2C), 120.13 (C), 103.94 (C), 84.63 (C),
53.95 (2C), 52.13 (2C), 51.92 (C), 47.12 (C); ESI-MS: m/z
359 (M+) and 361 (M + 2); Anal. Calcd. for C19H22ClN3O2:
C, 63.42, H, 6.16, N, 11.68, Found C, 63.40, H, 6.18, N,
11.65%.
2.3.5. 1-{[3-(furan-2-yl)-5-(4-bromophenyl)-4,5-dihydro-1,2-
oxazol-4-yl]methyl}-4 methyl piperazine (3e)
FT-IR (KBr pellet) cm1: 3162 (aromatic C–H stretch), 1678
(C‚N stretch), 1365 (C–O–N stretch), 1056 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.69–7.42 (t, 3H, furan), 7.58–7.10 (m, 4H, Ar–H),
5.29 (d, 1H, J= 6.3 Hz isoxazoline), 4.36 (m, 1H, isoxazoline),
3.48 (d, 2H, J= 6.5 Hz (CH2–N), 3.43–2.39 (t, 8H,
J= 4.2 Hz CH2–N–CH2 piperazine), 2.54 (s, 3H, N–CH3
piperazine); 13C NMR (75 MHz, DMSO-d6): d (ppm) 149.72
(C), 146.02 (C), 142.49 (C), 139.71 (C), 130.14 (2C), 129.41
(C), 128.86 (2C), 120.03 (C), 104.18 (C), 84.64 (C), 54.13
(2C), 52.03 (2C), 51.79 (C), 47.06 (C); ESI-MS: m/z 404
(M+) and 406 (M + 2); Anal. Calcd for C19H22BrN3O2: C,
56.44, H, 5.48, N, 10.39, Found C, 56.40, H, 5.52, N, 10.43%.
2.3.6. 1-{[3-(furan-2-yl)-5-(4-ﬂuorophenyl)-4,5-dihydro-1,2-
oxazol-4-yl]methyl}-4 methyl piperazine (3f)
FT-IR (KBr pellet) cm1: 3122 (aromatic C–H stretch), 1676
(C‚N stretch), 1366 (C–O–N stretch), 1052 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.92–7.70 (t, 3H, furan), 7.58–7.23 (m, 4H, Ar–H),
5.24 (d, 1H, J= 6.4 Hz isoxazoline), 4.32 (m, 1H, isoxazoline),
3.37 (d, 2H, J= 6.1 Hz (CH2–N), 3.22-2.57 (t, 8H, J= 4.5 Hz
CH2–N–CH2 piperazine), 2.55 (s, 3H, N–CH3 piperazine);
13C
NMR (DMSO-d6): d (ppm) 149.99 (C), 145.36 (C), 142.86 (C),
140.07 (C), 130.04 (2C), 129.44 (C), 128.89 (2C), 119.49 (C),
104.30 (C), 84.33 (C), 54.16 (2C), 52.10 (2C), 52.00 (C),
46.77 (C); ESI-MS: m/z 343 (M+); Anal. Calcd. for
C19H22FN3O2: C, 66.45, H, 6.46, N, 12.24, Found C, 66.43,
H, 6.48, N, 12.25%.2.3.7. 1-{[3-(furan-2-yl)-5-(4-hydroxyphenyl)-4,5-dihydro-1,2-
oxazol-4-yl]methyl}-4 methyl piperazine (3g)
FT-IR (KBr pellet) cm1: 3096 (aromatic C–H stretch), 1700
(C‚N stretch), 1364 (C–O–N stretch), 1052 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 8.47 (s, 1H, Ar–OH), 7.80–7.62 (t, 3H, furan), 7.20–
6.98 (m, 4H, Ar-H), 5.38 (d, 1H, J= 6.2 Hz isoxazoline),
4.31 (m, 1H, isoxazoline), 3.36 (d, 2H, J= 6.5 Hz (CH2–N),
3.29–2.63 (t, 8H, J= 4.7 Hz CH2–N–CH2 piperazine), 2.49
(s, 3H, N–CH3 piperazine);
13C NMR (75 MHz, DMSO-d6):
d (ppm) 149.87 (C), 145.45 (C), 142.66 (C), 139.53 (C),
129.64 (2C), 129.18 (C), 129.00 (2C), 119.39 (C), 104.10 (C),
84.48 (C), 53.68 (2C), 52.13 (2C), 51.78 (C), 46.72 (C); ESI-
MS: m/z 341 (M+); Anal. Calcd for C19H23N3O3: C, 66.84,
H, 6.79, N, 12.31, Found C, 66.80, H, 6.81, N, 12.29%.
2.3.8. 1-{[3-(furan-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1,2-
oxazol-4-yl]methyl}-4 methyl piperazine (3h)
FT-IR (KBr pellet) cm1: 3143 (aromatic C–H stretch), 1676
(C‚N stretch), 1367 (C–O–N stretch), 1043 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.72–7.68 (t, 3H, furan), 7.56–7.30 (m, 4H, Ar–H),
5.30 (d, 1H, J= 6.7 Hz isoxazoline), 4.33 (m, 1H, isoxazoline),
4.05 (s, 3H, Ar–OCH3), 3.33 (d, 2H, J= 6.2 Hz (CH2–N),
3.24–2.68 (t, 8H, J= 4.3 Hz CH2–N–CH2 piperazine), 2.53
(s, 3H, N–CH3 piperazine);
13C NMR (75 MHz, DMSO-d6):
d (ppm) 149.88 (C), 145.50 (C), 142.56 (C), 139.67 (C),
130.11 (2C), 129.33 (C), 128.87 (2C), 119.49 (C), 103.94 (C),
84.59 (C), 53.67 (2C), 52.14 (2C), 51.88 (C), 46.63 (C); ESI-
MS: m/z 355 (M+); Anal. Calcd. for C20H25N3O3: C, 67.58,
H, 7.09, N, 11.82, Found C, 67.55, H, 7.11, N, 1.79%.2.3.9. 1-{[3-(furan-2-yl)-5-(4-aminophenyl)-4,5-dihydro-1,2-
oxazol-4-yl]methyl}-4 methyl piperazine (3i)
FT-IR (KBr pellet) cm1: 3136 (aromatic C–H stretch), 1667
(C‚N stretch), 1360 (C–O–N stretch), 1046 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.58–7.32 (t, 3H, furan), 7.48–7.00 (m, 4H, Ar–H),
5.43 (d, 1H, J= 6.8 Hz isoxazoline), 5.01 (s, 2H, Ar–NH2),
4.27 (m, 1H, isoxazoline), 3.40 (d, 2H, J= 6.3 Hz (CH2–N),
3.30–2.59 (t, 8H, J= 4.4 Hz CH2–N–CH2 piperazine), 2.55
(s, 3H, N–CH3 piperazine);
13C NMR (75 MHz, DMSO-d6):
d (ppm) 149.82 (C), 145.45 (C), 142.43 (C), 139.62 (C),
129.70 (2C), 129.33 (C), 129.00 (2C), 119.39 (C), 104.17 (C),
84.58 (C), 53.67 (2C), 51.90 (2C), 51.85 (C), 46.68 (C); ESI-
MS: m/z 340 (M+); Anal. Calcd. for C19H24N4O2: C, 67.04,
H, 7.11, N, 16.46, Found C, 67.01, H, 7.09, N, 16.43%.
2.3.10. 1-{[3-(furan-2-yl)-5-(4-nitrophenyl)-4,5-dihydro-1,2-
oxazol-4-yl]methyl}-4 methyl piperazine (3j)
FT-IR (KBr pellet) cm1: 3137 (aromatic C–H stretch), 1678
(C‚N stretch), 1358 (C–O–N stretch), 1050 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.73–7.32 (t, 3H, furan), 7.60–7.02 (m, 4H, Ar–H),
5.36 (d, 1H, J= 6.2 Hz isoxazoline), 4.25 (m, 1H, isoxazoline),
3.40 (d, 2H, J= 6.5 Hz (CH2–N), 3.32–2.47 (t, 8H,
J= 4.6 Hz CH2–N–CH2 piperazine), 2.53 (s, 3H, N–CH3
piperazine); 13C NMR (75 MHz, DMSO-d6): d (ppm) 149.91
(C), 145.37 (C), 142.41 (C), 139.60 (C), 129.65 (2C), 129.34
(C), 128.94 (2C), 119.39 (C), 104.17 (C), 84.57 (C), 53.70
Design, synthesis and pharmacological evaluation of some novel derivatives 145(2C), 51.89 (2C), 51.72 (C), 46.66 (C); ESI-MS: m/z 370 (M+);
Anal. Calcd. for C19H22N4O4: C, 61.61, H, 5.99, N, 15.13,
Found C, 61.59, H, 5.89, N, 15.10%.
2.3.11. 1-{[3-(furan-2-yl)-5-(4-N,N-dimethylaminophenyl)-
4,5-dihydro-1,2-oxazol-4-yl]methyl}-4 methyl piperazine (3k)
FT-IR (KBr pellet) cm1: 3120 (aromatic C–H stretch), 1680
(C‚N stretch), 1360 (C–O–N stretch), 1045 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.80–7.70 (t, 3H, furan), 7.60–7.00 (m, 4H, Ar–H),
5.33 (d, 1H, J= 6.3 Hz isoxazoline), 4.30 (m, 1H, isoxazoline),
3.43 (d, 2H, J= 6.7 Hz (CH2–N), 3.30-2.51 (t, 8H, J= 4.2 Hz
CH2–N–CH2 piperazine), 2.51 (s, 3H, N–CH3 piperazine), 2.27
(s, 6H, 2 · CH3); 13C NMR (75 MHz, DMSO-d6): d (ppm)
149.90 (C), 145.42 (C), 142.49 (C), 139.60 (C), 129.75 (2C),
129.28 (C), 128.97 (2C), 119.41 (C), 104.13 (C), 84.56 (C),
53.72 (2C), 51.95 (2C), 51.80 (C), 46.79 (C); ESI-MS: m/z
368 (M+); Anal. Calcd. for C21H28N4O2: C, 68.45, H, 7.66,
N, 15.21, Found C, 68.47, H, 7.64, N, 15.19%.2.3.12. 1-{[3-(furan-2-yl)-5-(3,4-dimethoxyphenyl)-4,5-
dihydro-1,2-oxazol-4-yl]methyl}-4 methyl piperazine (3l)
FT-IR (KBr pellet) cm1: 3123 (aromatic C–H stretch), 1682
(C‚N stretch), 1367 (C–O–N stretch), 1045 (furan C–O–C
stretching); 1H NMR (400 MHz, DMSO-d6, 25 C, TMS): d
(ppm) 7.90–7.65 (t, 3H, furan), 7.66–7.00 (m, 4H, Ar–H),
5.39 (d, 1H, J= 6.5 Hz isoxazoline), 4.34 (m, 1H, isoxazoline),
3.81 (s, 6H, 2 · O–CH3), 3.43 (d, 2H, J= 6.7 Hz (CH2–N),
3.34–2.48 (t, 8H, J= 4.9 Hz CH2–N–CH2 piperazine), 2.54
(s, 3H, N–CH3 piperazine);
13C NMR (75 MHz, DMSO-d6):
d (ppm) 149.89 (C), 145.39 (C), 142.49 (C), 139.59 (C),
129.78 (2C), 129.29 (C), 128.95 (2C), 119.40 (C), 104.10 (C),
84.56 (C), 53.72 (2C), 51.91 (2C), 51.80 (C), 46.73 (C); ESI-
MS: m/z 385 (M+); Anal. Calcd. for C21H27N3O4: C, 65.44,
H, 7.06, N, 10.90, Found C, 65.47, H, 7.07, N, 10.93%.Table 2 Antidepressant activity of the newly synthesized compoun
Compounds Antidepressan
Immobility tim
(mean ± SEM
3a 152.33 ± 0.84
3b 164.50 ± 0.76
3c 163.17 ± 0.60
3d 160.50 ± 0.76
3e 163 ± 0.93
3f 162.83 ± 0.70
3g 158.50 ± 0.76
3h 156.50 ± 1.47
3i 166.83 ± 1.07
3j 157.67 ± 1.22
3k 152 ± 0.57
3l 162 ± 0.89
Imipramine 149.67 ± 0.84
Control 167.17 ± 0.60
Values represent the mean ± SEM (n= 6).
a Signiﬁcant compared to control (Dunnet’s test; p< 0.05).
b Most signiﬁcant compared to control (Dunnet’s test; p< 0.01).2.4. Antidepressant activity (forced swim test in mice)
Swiss albino mice (20–24 g) were used for the forced swimming
test under standard conditions with free access to food and
water. They were housed in groups of six. On the test day mice
were dropped once at a time into a Plexiglass cylinder contain-
ing 10 cm of water at 23–25 C (Porsolt et al., 1977). On the
testing day, mice were assigned into different groups (n= 6
for each group). The synthesized compounds were screened
for their antidepressant activity using Porsolt’s behavioral des-
pair (forced swimming) test. Brieﬂy, the mice were individually
placed in a glass cylinder (25 cm high; 10 cm in diameter) con-
taining 6 cm of water kept at 23–25 C, and were left therein
for 6 min. The synthesized compounds (10 mg kg1), and imip-
ramine, as a reference antidepressant drug (10 mg kg1) were
suspended in a 1% aqueous solution of Tween 80. The drugs
were injected intraperitoneally (ip) in a standard volume of
0.5 ml/20 g body weight, 1 h prior to the test. Control animals
received 1% aqueous solution of Tween 80. Then, the mice
were dropped individually into the Plexiglass cylinder and left
in the water for 6 min. For the ﬁrst 2 min of initial vigorous
struggling the animals were immobile. Immobility time is the
time spent by mice ﬂoating in water without struggling, mak-
ing only those movements necessary to keep the head above
the water. The total duration of immobility was recorded dur-
ing the last 4 min of the 6 min test session. The data of antide-
pressant activity are given in Table 2.
2.5. Anxiolytic activity (elevated plus maze test in mice)
Swiss albino mice, weighing 20–24 g each, were selected
from the stock colony maintained in the central animal facil-
ity with free access to food and water. Animals were main-
tained in an air-conditioned room. The room was
maintained at 25 ± 2 C with natural daytime. Concentra-
tion of each compound (10 mg/kg) was used in the formds (forced swim test in mice).
t activity
e (s)
)
Change from
control (%)
b 8.88
1.60
a 2.39
b 3.99
a 2.49
a 2.60
b 5.19
b 6.38
0.20
b 5.68
b 9.07
b 3.09
b 10.47
–
Table 3 Anti anxiety activity of the newly synthesized compounds (elevated plus maze test in mice).
Compounds % Preference to open arm Open arm
No. of entries
(mean ± SEM)
Average time
spent (mean ± SEM)
3a 14.17 4.33 ± 0.42b 42.50 ± 0.76b
3b 6.00 2.16 ± 0.30 18 ± 0.57
3c 6.83 2.33 ± 0.21 20.50 ± 0.76b
3d 11.50 3.33 ± 0.21a 34.50 ± 0.76b
3e 9.83 3.50 ± 0.34a 29.50 ± 0.76b
3f 6.94 3 ± 0.36 ns 20.83 ± 0.94b
3g 12.17 3.83 ± 0.30b 36.50 ± 0.76b
3h 6.39 3.50 ± 0.22a 19.16 ± 0.79a
3i 6.33 2.50 ± 0.22 19 ± 0.57
3j 6.50 2.66 ± 0.33 19.50 ± 0.99a
3k 15.11 4.16 ± 0.30b 45.33 ± 0.66b
3l 5.72 2.33 ± 0.42 17.16 ± 0.94
Control 5.33 2 ± 0.25 16.0 ± 0.57
Diazepam 19.50 4.83 ± 0.47b 58.50 ± 0.76b
Values represent the mean ± SEM (n= 6).
a Signiﬁcant compared to control (Dunnet’s test; p< 0.05).
b Most signiﬁcant compared to control (Dunnet’s test; p< 0.01).
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tions were prepared freshly on test days and given intraper-
itoneally (ip) in a volume of 0.5 ml/20g body weight of mice.
The experimental animals were treated with Diazepam
(2 mg/ kg, n= 6), or the compounds (10 mg/kg) 60 min be-
fore evaluation in the maze. The control group was given
saline with 1% tween 80.
Plus maze for mice (Moser, 1989; Rabbani et al., 2004; Pel-
low et al., 1985; Kulkarni, 2002) consisted of two open
(16 · 5 cm2) and two closed arms (16 · 5 · 12 cm3) facing each
other with an open roof. The entire maze is elevated to a height
of 25 cm. In the test, mice were individually examined in 5 min
sessions in this apparatus. Each mouse was placed in the cen-
tral platform facing one open arm. The numbers of entries into
open and closed arms and the time spent in the respective arms
were recorded during a 5 min period. The percentage of time
spent in the open arms [(open/open + closed) · 100] was cal-
culated for each mouse. The results of EPM have been summa-
rized in Table 3.
2.6. Neurotoxicity
The rotarod test was used to evaluate neurotoxicity. The ani-
mal was placed on a 1 inch diameter knurled wooden rod
rotating at 6 rpm. Normal mice remain on a rod rotating at
this speed indeﬁnitely. Neurologic toxicity was deﬁned as the
failure of the animal to remain on the rod for 1 min.
2.7. Statistical analysis
Results are expressed as mean SEM; n represents the number
of animals. Data obtained from pharmacological experiments
were analyzed by one way analysis of variance (ANOVA) fol-
lowed by Dunnet’s test and used to evaluate the results, using
InStat GraphPad (version 3.06, GraphPad Software Inc., San
Diego, CA, USA). A p-value of less than 0.05 was considered
statistically signiﬁcant.2.8. Docking study
The docking analysis of most active molecule was performed
using Maestro, version 9.2 implemented from Schrodinger
molecular modeling suite. The molecules were sketched in
the 3D format using build panel and LigPrep module was used
to produce low-energy conformers. The crystal structure of
MAO-A (PDB ID: 2BXR) was obtained from protein data
bank. The protein was prepared by giving preliminary treat-
ment like adding hydrogen, adding missing residues, reﬁning
the loop with prime and ﬁnally minimized by using OPLS-
2005 force ﬁeld. Grid for molecular docking was generated
with bound co-crystallized ligand. Molecules were docked
using Glide in extra-precision mode, with up to three poses
saved. Ligands were kept ﬂexible by producing the ring confor-
mations and by penalizing non-polar amide bond conforma-
tions, whereas the receptor was kept rigid throughout the
docking studies. All other parameters of the Glide module
were maintained at their default values. The lowest energy con-
formation was selected for the prediction of ligand interactions
with the active sites of MAO-A.
3. Results and discussion
3.1. Chemistry
The reaction routes for the synthesis of the title compounds
were described in scheme 1. Structures, yields and melting
points of the compounds are listed in Table 1. All spectral data
are in accordance with expected structures. The IR spectra of
the compounds provided information of isoxazoline C‚N
stretching (1666–1700 cm1), isoxazoline C–O–N stretching
(1336–1367 cm1), aromatic C–H stretching (3096–
3162 cm1), and furan C–O–C stretching (1043–1068 cm1)
bands.
The 1H NMR spectra of the compound (3a) d (ppm) show:
7.89–7.72 (t, 3H, furan); 7.61–7.03 (m, 5H, Ar–H); 5.34 (d, 1H,
Scheme 1 Synthetic route for the preparation of 1-{[3-(furan-2-yl)-5-phenyl-4,5-dihydro-1,2-oxazol-4-yl]methyl}-4 methyl Piperazine
derivatives (3a-l).
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2H, J= 6.2 Hz (CH2–N), 3.27-2.54 (t, 8H, J= 4.6 Hz CH2–
N–CH2 piperazine), 2.51 (s, 3H, N–CH3 piperazine). In the
mass spectra of the compounds, molecular ions (M+) were
observed.
3.2. Biology
The forced swimming test is a behavioral test used to predict
the efﬁcacy of antidepressant treatments (Porsolt et al.,
1977). It is used efﬁcaciously in predicting the activity of a wide
variety of antidepressants such as MAO inhibitors and atypi-
cal antidepressants. It has a strong predictive value for antide-
pressant potency in humans. The obtained data on the
antidepressant activity of the compounds and reference drugFigure 1 Binding pattern and interaction of 3a (a) aare given in Table 2. In the present study, 1-{[3-(furan-2-yl)-
5-(4-N,N-dimethylamino phenyl)-4,5-di hydro-1,2-oxazol-4-
yl]methyl}-4 methyl piperazine (3k) and 1-{[3-(furan-2-yl)-5-
phenyl-4,5-dihydro-1,2-oxazol-4-yl]methyl}-4 methyl pipera-
zine (3a) signiﬁcantly reduced the duration of immobility times
at 10 mg kg1 dose level when compared to control (p< 0.05,
Table 2). All the substitutions were made at the phenyl ring to
evaluate their structure activity relationship. The antidepres-
sant activity of the synthesized compounds having p-N, N-
(CH3)2 (3k), un-substituted phenyl (3a) and p-O–CH3 (3h)
groups at the para position of phenyl ring was signiﬁcantly re-
duced (immobility time 6.38 to 9.07%). However, the para
substituted compounds like p-CH3 (3b), p-Cl (3d), p-Br (3e), p-
F (3f) and p-NH2 (3i) groups moderately decreased the immo-
bility time with respect to control.nd 3k (b) at the binding site of MAO-A enzyme.
Figure 2 Docking orientations of 3a (a) and 3k (b) at the binding surface of the enzyme.
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were also investigated, and results from these experiments
are shown in Table 3. Compounds 3a, 3g and 3k were found
to have most potent anxiolytic activity using the elevated plus
maze method. Neurotoxicity was observed in none of the syn-
thesized compounds in the dose of 10 mg kg1.
3.3. Docking analysis
Docking analysis was performed using both most active mole-
cules. In silico modeling studies predicted good binding modes
of 3a and 3kwith the binding site ofMAO-A enzyme.Molecules
are interacting by good hydrogen bonding with the active site
residues of protein. Molecule 3a is making two hydrogen bonds
withGly-22, Ser-24 andArg-45 while, molecule 3k is interacting
with Ala-68 and Tyr-69 by hydrogen bonding (Fig. 1). Both of
the molecules were well occupied in the binding site pocket of
the enzyme. Fig. 2 represents the binding orientation of both
molecules at the binding site surface of the protein.
4. Conclusion
The research study reports the successful synthesis of com-
pounds 3a–l. The synthesized compounds 3k and 3a have
shown substantial anti-depressant activity, and also due to
the presence of a furyl substituent at the third position and
phenyl substituent at the ﬁfth position of the isoxazoline ring
(3k and 3a) possess remarkable anti-anxiety activity. There-
fore, they seem to be extremely anticipating compounds for
their antianxiety activities. The synthesis studies should be ex-
tended concerning this group of compounds followed by fur-
ther clinical studies. The molecular modeling studies also
predicted good binding interactions of most active molecules
with the MAO-A. Therefore, it can be safely concluded that
compounds 3k and 3a would represent a useful model for fur-
ther investigation in the development of a new class of dual
anti-depressant and anti-anxiety agents.Acknowledgments
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